The IOPtiMate laser-based system, from the Bio-Light Group, used for the non-invasive filtration treatment of glaucoma has received European Patent Office approval.
The technology is a CO2 laser-based system which enables the filtration procedure for the alleviation of Intra Ocular Pressure.
According to Dr. Ami Eya, CEO of Bio-Light,The EPO approval will enable commercialization of our systems in a protected and proprietary environment. It was a short while ago when we received the CE mark of approval and we are currently preparing for the implementation of our systems in the European markets parallel to the implementation in the Far East markets which has already begun. We are continuing our process of achieving FDA approval and expect to begin clinical trials in the US shortly.
Dr Joshua Degani, IOPtima CEO says, Receiving the EPO approval is another important milestone for IOPtima which further validates and strengthens our position towards launching our product in Europe. Recently, we have obtained a CE mark of approval after successfully completing clinical testing in leading medical centres in Europe, Italy, Spain, and Russia. We believe that we can provide an effective and viable solution to millions of people suffering from this chronic eye disease that require constant treatment.
It is estimated that by 2010, approximately 12 million people in Europe, will suffer from glaucoma. The cost of medication treatment of glaucoma, the currently most common form of treatment, is estimated to be above $3 billion every year worldwide.